Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Company Overview

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications. Its lead candidate has advanced into initial human trials, and additional assets are in IND-enabling studies. To support development, the company collaborates with academic research institutions and specialty contract development organizations, drawing on external expertise for pharmacology, toxicology and clinical trial execution.

Based in the United States with operations in Europe, Eledon Pharmaceuticals conducts multi-center studies across North America and the EMEA region. The company’s leadership team brings together experienced drug development professionals, clinical operations specialists and regulatory experts, positioning Eledon to advance its portfolio toward late-stage trials and eventual commercialization.

Key Stats

• Today's Range: $2.65 to $2.71
• 50-Day Range: $2.55 to $3.91
• 52-Week Range: $2.38 to $5.54
• Volume: 101,844 shs
• Average Volume: 436,437 shs
• Market Capitalization: $160.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Eledon Pharmaceuticals Stock Analysis - MarketRank™

Eledon Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 696th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eledon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Eledon Pharmaceuticals has a consensus price target of $10.00, representing about 273.1% upside from its current price of $2.68.

Amount of Analyst Coverage

Eledon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Eledon Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eledon Pharmaceuticals is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eledon Pharmaceuticals is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eledon Pharmaceuticals has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.12% of the outstanding shares of Eledon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently increased by 24.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eledon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eledon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.12% of the outstanding shares of Eledon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently increased by 24.94%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.26

News Sentiment

Eledon Pharmaceuticals has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

4 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELDN Stock Analysis - Frequently Asked Questions

How have ELDN shares performed this year?

Eledon Pharmaceuticals' stock was trading at $4.12 at the start of the year. Since then, ELDN stock has decreased by 35.0% and is now trading at $2.68.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) announced its earnings results on Thursday, August, 14th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.10.

Who are Eledon Pharmaceuticals' major shareholders?

Top institutional shareholders of Eledon Pharmaceuticals include First Light Asset Management LLC (4.34%), Geode Capital Management LLC (2.31%), Velan Capital Investment Management LP (0.57%) and Boothbay Fund Management LLC (0.49%).
View institutional ownership trends.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eledon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELDN
• CIK: 1404281
• Web: novustherapeutics.com
• Phone: (949) 238-8090
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eledon Pharmaceuticals: $10.00
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +273.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.18 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -92.51%
• Return on Assets: -38.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.12
• Quick Ratio: 8.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 2.55

Miscellaneous

• Outstanding Shares: 59,880,000
• Free Float: 52,517,000
• Market Cap: $160.48 million
• Optionable: Optionable
• Beta: -0.12